Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Fudan-University-Shanghai-Cancer-Center"

3 News Found

Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
Clinical Trials | June 03, 2026

Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types

The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
Drug Approval | March 31, 2026

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

ENHERTU gains first-ever nod in China for metastatic breast cancer
Drug Approval | December 29, 2025

ENHERTU gains first-ever nod in China for metastatic breast cancer

The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging